Updated Jul 16, 2026
Vogt Frederick G has filed 2 SEC Form 4 filings across 1 company in the last 90 days.

Frederick G. Vogt is a corporate executive known for his roles at Iovance Biotherapeutics, Inc., where he has served as Director, Interim CEO, and General Counsel. He has been involved in the company's efforts to advance innovative cancer therapies.
| Role | Interim CEO & General Counsel, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-09 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 6.6K | $4.23 | $28K |
| 2026-06-09 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 15.6K | $0.00 | |
| 2026-06-03 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 17.7K | $3.96 | $70K |
| 2026-06-03 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 41.7K | $0.00 | |
| 2026-03-06 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 26.8K | $4.58 | $123K |
| 2026-03-06 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 62.5K | $0.00 | |
| 2026-03-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 22.8K | $3.79 | $86K |
| 2026-03-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 52.1K | $0.00 | |
| 2025-09-02 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 22.1K | $2.19 | $48K |
| 2025-09-02 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 52.1K | $0.00 | |
| 2024-12-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 4.4K | $9.07 | $40K |
| 2024-12-04 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 10.4K | $0.00 | |
| 2024-10-16 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | F — Tax withholding / forfeiture | 8.9K | $9.77 | $86K |
| 2024-10-16 | IOVA | IOVANCE BIOTHERAPEUTICS, INC. | M — Option exercise | 20.8K | $0.00 |
Frederick G. Vogt is a corporate executive known for his roles at Iovance Biotherapeutics, Inc., where he has served as Director, Interim CEO, and General Counsel. He has been involved in the company's efforts to advance innovative cancer therapies.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Vogt Frederick G profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.